A year in pharma and biotech R&D: Lack of large M&As leads to little change
This article was originally published in Scrip
No surprises in the top 10, but the number of smaller companies involved in R&D, including a wealth of start-ups, continues on its unrelenting growth trajectory.
You may also be interested in...
Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.
GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.
A decade ago, the publication of the human genome foreshadowed an explosion in new drug targets. Those predictions now seem to have been overly optimistic.